Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It is time to change the breakpoint

Lindsay M. Avery, Joseph L. Kuti, Maja Weisser, Adrian Egli, Michael J. Rybak, Evan J. Zasowski, Cesar A. Arias, German A. Contreras, Pearlie P. Chong, Samuel L. Aitken, Adam J. DiPippo, Jann Tay Wang, Nicholas S. Britt, David P. Nicolau

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Background. Currently, there is debate over whether the daptomycin susceptibility breakpoint for enterococci (ie, minimum inhibitory concentration [MIC] ≤4 mg/L) is appropriate. In bacteremia, observational data support prescription of high doses (>8 mg/kg). However, pharmacodynamic targets associated with positive patient outcomes are undefined. Methods. Data were pooled from observational studies that assessed outcomes in daptomycin-treated enterococcal bacteremia. Patients who received an additional antienterococcal antibiotic and/or a β-lactam antibiotic at any time during treatment were excluded. Daptomycin exposures were calculated using a published population pharmacokinetic model. The free drug area under the concentration-time curve to MIC ratio (fAUC/MIC) threshold predictive of survival at 30 days was identified by classification and regression tree analysis and confirmed with multivariable logistic regression. Monte Carlo simulations determined the probability of target attainment (PTA) at clinically relevant MICs. Results. Of 114 patients who received daptomycin monotherapy, 67 (58.8%) were alive at 30 days. A fAUC/MIC >27.43 was associated with survival in low-acuity (n = 77) patients (68.9 vs 37.5%, P = .006), which remained significant after adjusting for infection source and immunosuppression (P = .026). The PTA for a 6-mg/kg/day (every 24 hours) dose was 1.5%-5.5% when the MIC was 4 mg/L (ie, daptomycin-susceptible) and 91.0%-97.9% when the MIC was 1 mg/L. Conclusions. For enterococcal bacteremia, a daptomycin fAUC/MIC >27.43 was associated with 30-day survival among low-acuity patients. As pharmacodynamics for the approved dose are optimized only when MIC ≤1 mg/L, these data continue to stress the importance of reevaluation of the susceptibility breakpoint.

Original languageEnglish (US)
Pages (from-to)1650-1657
Number of pages8
JournalClinical Infectious Diseases
Issue number10
StatePublished - May 1 2019


  • Bacteremia
  • Daptomycin
  • Enterococcus
  • Pharmacodynamics

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It is time to change the breakpoint'. Together they form a unique fingerprint.

Cite this